BLEEDnFIRE Therapeutics AG

BLEEDnFIRE Therapeutics is a biotech company developing first-in-class RNAi therapies to rebalance hemostasis in severe bleeding disorders. Our lead program, BnF-001, selectively targets Protein S to restore thrombin generation and provide durable bleed protection without factor replacement, addressing key limitations of current therapies across disorders such as von Willebrand disease, Glanzmann thrombasthenia and hemophilia. Beyond bleeding control, the approach has the potential to improve long-term joint and bone health, a major source of morbidity in these patients.

BLEEDnFIRE has secured a strong intellectual property position, including granted patents and additional patent applications. The team combines complementary expertise in hem